RxDoctor Payments Data

Shital Hubli, MD

Family Medicine · Tracy, CANPI 1053339127

Payments from drug & device makers

$9,292in general payments, 2019–2025

Across 496 payments — averaging $18.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$1K
  • Lilly USA, LLC$865
  • Bayer$603
  • Merck$352
  • Sumitomo Pharma America, Inc.$344
  • plus $4K from 47 others

What the payments were for

  • Food & beverage$9,292100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,292 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$596,726
Medicare patients
700
Services billed
6,157

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide293$332,635
JardianceEmpagliflozin142$184,481
EliquisApixaban198$149,421
MounjaroTirzepatide101$114,238
FarxigaDapagliflozin Propanediol104$113,222
XareltoRivaroxaban71$77,548
ProliaDenosumab36$59,896
EntrestoSacubitril/Valsartan22$37,741
RybelsusSemaglutide16$35,463
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$34,995
TrulicityDulaglutide29$33,316
JanuviaSitagliptin Phosphate22$25,544
Repatha SureclickEvolocumab34$19,385
LinzessLinaclotide28$18,792
MultaqDronedarone Hcl11$17,119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,588$368,099309 claims
Boehringer IngelheimJardiance, Tradjenta$318$197,280153 claims
PfizerEliquis, Premarin$172$156,603220 claims
Lilly USA, LLCMounjaro, Trulicity$865$147,554130 claims
AstraZenecaFarxiga, Symbicort$1,351$119,189123 claims
Johnson & JohnsonXarelto$127$77,54871 claims
AmgenProlia$342$59,89636 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$324$53,53391 claims
NovartisEntresto$39$37,74122 claims
MerckJanuvia$352$25,54422 claims
AbbVieLinzess$215$18,79228 claims
Sanofi-aventis U.S. LLCMultaq$308$17,11911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Tracy

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →